{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-031255","form_type":"8-K","ticker":"ADGM","cik":"0002006986","company_name":"Adagio Medical Holdings, Inc.","filed_at":"2025-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.672368+00:00","generated_at":"2026-05-24T00:06:39.420079+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Adagio Medical reports FY2024 revenue up 101% to $0.6M, net loss widens to $75M, appoints CBO","bullets":["Full year revenue $0.6M (+101% YoY); net loss $75.0M vs $36.6M prior year, driven by $49.2M impairment charge.","Q4 revenue $137K (+76% YoY); net loss $57.4M vs $8.6M; gross margin negative 1012%.","Cash and short-term investments $20.6M as of Dec 31, 2024.","FULCRUM-VT pivotal study enrollment over 40%; completion target H2 2025.","Appointed Deborah Kaster as Chief Business Officer, effective March 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-031255","json":"https://secwatch.observer/filing/0001104659-25-031255.json","markdown":"https://secwatch.observer/filing/0001104659-25-031255.md","text":"https://secwatch.observer/filing/0001104659-25-031255.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006986/000110465925031255/0001104659-25-031255-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006986/000110465925031255/tm2511083d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T00:06:39.420079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}